EFTA00603737Set 9
17p11,455w
metastatic lesion is assumed to have all the driver gene mutations
large tumour often contains the same core set of genetic altera- needed to expand. Motivated by histopathological images ... model the lesion as a conglomerate of balls of cells (see Methods and
during tumour growth'''. How such alterations expand within the Extended Data Fig. 1). Cells occupy sites ... regular three-dimen-
spatially constrained three-dimensional architecture of a tumour, sional lattice (Extended Data Fig. 2a, b). Cells replicate stochastically
and come to dominate a large, pre-existing lesion
https://www.justice.gov/epstein/files/DataSet%209/EFTA00603737.pdf
EFTA00309574Set 9
2014-04-282p1,111w
highlight the immuno-onocolgy
opportunity. Beyond bladder cancer data at ASCO, potential in other tumours
and the data in combination with Avastin, if positive, have the potential to Bloomberg JPMA ... Mare pd.* (SwF)
MSCI-Fu Ireben41
• Roche continues to explore PD-L1 in further tumour types, although YM 1m 3m 12m
there are no timelines for disclosure or data presentation ... conference call Roche highlighted that they continue to explore PD-
L I in other tumour types, for which they will release data as they become
mature. Based on disclosed Phase
https://www.justice.gov/epstein/files/DataSet%209/EFTA00309574.pdf
EFTA01197764Set 9
8p3,954w
being studied as a target for cancer drugs. Inhibition of
PLK1 expression prevents the tumour cell from completing cell division, resulting in cell cycle
arrest and death of the cancer ... silence PLK1. The clinical trials have been conducted with patients
who have Gastrointestinal Neuroendocrine Tumours (GI-NET), Adrenocortical Carcinoma
(ACC) and will soon begin a Hepatocellural Carcinoma ... patients with GI-NET
remains a challenge, and currently there are no approved anti-tumour drug
treatments indicated specifically for GI-NET.
✓ HCC — Primary liver cancer, or hepatocellular carcinoma
https://www.justice.gov/epstein/files/DataSet%209/EFTA01197764.pdf
EFTA00910530Set 9
2011-05-122p777w
never know.
If it is a situation where the you need to stall the tumours growth
and you are in a wait and see time frame, I personally would consult ... always new research
coming out about foods that have anti cancer, and more importantly
tumour retarding properties. This is a special interest of mine, so I
can send you information ... issues of my own, as you know, and of late
they have discovered some tumours on my thyroid with need further
evaluation. Apparently that is a common benign issue
https://www.justice.gov/epstein/files/DataSet%209/EFTA00910530.pdf
EFTA01862501Set 10
2011-05-113p776w
never know.
If it is a situation where the you need to stall the tumours growth
and you are in a wait and see time frame, I personally would consult ... EFTA01862501
coming out about foods that have anti cancer, and more importantly
tumour retarding properties. This is a special interest of mine, so i
can send you information ... issues of my own, as you know, and of late
they have discovered some tumours on my thyroid with need further
evaluation. Apparently that is a common benign issue
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01862501.pdf
EFTA02714282Set 11
8p3,952w
being studied as a target for cancer drugs. Inhibition of
PLK1 expression prevents the tumour cell from completing cell division, resulting in cell cycle
arrest and death of the cancer ... silence PLK1. The clinical trials have been conducted with patients
who have Gastrointestinal Neuroendocrine Tumours (GI-NET), Adrenocortical Carcinoma
(ACC) and will soon begin a Hepatocellural Carcinoma ... patients with GI-NET
remains a challenge, and currently there are no approved anti-tumour drug
treatments indicated specifically for GI-NET.
• HCC — Primary liver cancer, or hepatocellular carcinoma
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02714282.pdf
EFTA02708217Set 11
3p1,438w
host
that is the key to survival and not the nature of the tumour. This is music to our ears!
It makes me feel like St John the Baptist!!
EFTA ... immune system can "see" it and attack. The key is to unmask the tumour
which, like a parasite, hides itself from recognition.
Finally, we are also anticipating some nice data ... even though
the cancer may not get smaller, these patients often live with their tumour and have
a good quality of life as well as survival. This
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02708217.pdf
EFTA00266821Set 9
2020-05-2629p6,743w
types to avoid
damage to surrounding tissues, leading to targeted necrosis (death) of cancer tumours.
Depending on the location and size of the 'liquefied' cancer tissues, these will either ... that would administer the selected
bioactive agents from the spider venoms directly into the tumours, leading to their
destruction in situ. By this mechanism, the cells from a cancer mass
https://www.justice.gov/epstein/files/DataSet%209/EFTA00266821.pdf
EFTA01800803Set 10
2014-04-276p2,857w
picture from Horvath's method is less clear. Some cancers, such as brain tumours, seemed
to be decades older, in terms of their methylation, than they should ... reversed for some other
cancers, such as certain types of endometrial and breast tumours.
Distortions in epigenetic age seem to parallel other diseases more closely. Horvath says that recent work
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01800803.pdf